^
Association details:
| Biomarker: | CD19 underexpression |
|---|---|
| Cancer: | Non-Hodgkin’s Lymphoma |
| Drug: | CLN-978 (CD3 agonist, CD19 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1024 CLN-978, a novel CD19/CD3/HSA T cell engager with extended serum half-life, is effective against lymphoma cells expressing very low levels of CD19
Published date:
11/04/2023
Excerpt:
CLN-978 elicited potent efficacy against B cell lymphoma cells expressing very low levels of hCD19...The characteristics of CLN-978...translate into high response rates and longer response duration in NHL patients expressing normal and very low levels of CD19 on malignant B cells.
DOI:
10.1136/jitc-2023-SITC2023.1024
